Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma.

Bibliographic Details
Title: Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma.
Authors: Seneviratne, Janith A., Ravindrarajah, Daenikka, Carter, Daniel R., Zhai, Vicki, Lalwani, Amit, Krishan, Sukriti, Balachandran, Anushree, Ng, Ernest, Pandher, Ruby, Wong, Matthew, Nero, Tracy L., Wang, Shudong, Norris, Murray D., Haber, Michelle, Liu, Tao, Parker, Michael W., Cheung, Belamy B., Marshall, Glenn M.
Source: Cancer Medicine; Nov2024, Vol. 13 Issue 21, p1-20, 20p
Subject Terms: MOLECULAR biology, HISTONE methyltransferases, GENE expression, ENDOPLASMIC reticulum, TUMOR markers, NEUROBLASTOMA
Abstract: Background: The child cancer, neuroblastoma (NB), is characterised by a low incidence of mutations and strong oncogenic embryonal driver signals. Many new targeted epigenetic modifier drugs have failed in human trials as monotherapy. Methods: We performed a high‐throughput, combination chromatin‐modifier drug screen against NB cells. We screened 13 drug candidates in 78 unique combinations. Results: We found that the combination of two histone methyltransferase (HMT) inhibitors: GSK343, targeting EZH2, and SGC0946, targeting DOT1L, demonstrated the strongest synergy across 8 NB cell lines, with low normal fibroblast toxicity. High mRNA expression of both EZH2 and DOT1L in NB tumour samples correlated with the poorest patient survival. Combination HMT inhibitor treatment caused activation of ATF4‐mediated endoplasmic reticulum (ER) stress responses. In addition, glutathione and several amino acids were depleted by HMT inhibitor combination on mass spectrometry analysis. The combination of SGC0946 and GSK343 reduced tumour growth in comparison to single agents. Conclusion: Our results support further investigation of HMT inhibitor combinations as a therapeutic approach in NB. [ABSTRACT FROM AUTHOR]
Copyright of Cancer Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:20457634
DOI:10.1002/cam4.70082
Published in:Cancer Medicine
Language:English